Encephalitis Treatment Market Future Scenario, Key Insights, Top Companies 2033 | FMI

The global Encephalitis Treatment Market is currently valued at US$ 20.14 Billion in 2023 and is anticipated to expand at a CAGR of 5.4%. Owing to the technological advances in healthcare the market is likely to propel to US$ 34.08 Billion by 2033.



The major factor attributing to the growth of the market is the high mortality and morbidity rate caused due to the incidence of encephalitis virus. Furthermore, increasing government initiatives for vaccination programs is boosting the market. As the number of cases and fatalities rises, individuals must take preventive measures such as immunisation, which increases demand for encephalitis treatment, thereby boosting the market growth.

For more information: https://www.futuremarketinsights.com/reports/encephalitis-treatment-market

The high disposable income, rising geriatric population, and changing lifestyles will result in the expansion of the encephalitis treatment market. Increasing research and development activities and increasing investments by government and private organization will boost new opportunities for the market's growth rate.

 The manufacturers are involved in the production of encephalitis treatment market in a larger capacity. Research and innovation are also conducted to launch innovative products for encephalitis treatment.

North America dominates the encephalitis treatment market due to the presence of key market players' presence, along with recent product launches and established healthcare infrastructure, which will accelerate the market's growth in the region. The significant R&D investments in Europe abode well for market growth.

Key Takeaways from the Market Study

·        As of 2023, the encephalitis treatment market was valued at US$20.14 Billion

·         From 2023 to 2033, the encephalitis treatment industry is poised to grow at 5.4% CAGR

·        By 2033, the encephalitis treatment market is slated to reach a valuation of US$ 34.08 Billion

·        Based on the end-users, the hospital pharmacy segment accounts for   market share of 50.5% during the forecast period. 

·        China is poised to yield a CAGR of 4.8% with to respect encephalitis treatment in 2033.

“Growing healthcare spending and growing the incidence of encephalitis across the world and rapid rise in the geriatric population are expected to radically transform the market in the coming years,” comments an analyst at FMI.

Competitive Landscape

Some of the key players present in the global encephalitis treatment markets are Allergan, Merck & Co., Inc., Pfizer Inc., GlaxoSmithKline plc, Melinta Therapeutics LLC, Basilea Pharmaceutica Ltd., Abbott, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi, and others.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

·         In December 2022, The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). In May 2022, Dupixent 300 mg weekly was approved by the U.S. Food and Drug Administration for the treatment of patients aged 12 years and older, weighing at least 40 kg.

·         In February 2021, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac™, its tick-borne encephalitis (TBE) vaccine for active immunization to prevent TBE in individuals 1 year of age and older.

Comments

Post a Comment

Popular posts from this blog

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more

Hemostasis Products Market Key Players, Applications, Outlook, SWOT Analysis And Forecasts by 2032

Image
  The global Hemostasis Products Market is expected to be worth US$ 1580 million in 2022. The market is expected to be worth US$ 2638 million between 2022 and 2032, at a CAGR of 5.3%. The rising prevalence of chronic blood disorders can be attributed to the market's expansion. High-level technological advancements, strong economies, and a swarming pool of patients with a variety of blood disorders are the chief factors that will boost the market for hemostasis products in the near future. The leading causes of surgeries are cardiovascular disease and stroke, cancer, and injury. And any surgical procedure can develop severe complications and result in uncontrollable bleeding thus increasing the demand for hemostasis products. Get a Sample Copy of the Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15386 The rapidly growing medical tourism sector coupled with the high investment made by governments of various countries towards the growth of the healthcare s...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more